Prevention & lipidsMeta-analysis

Alternative LDL Cholesterol–Lowering Strategy vs High-Intensity Statins in Atherosclerotic Cardiovascular Disease

JAMA CardiolPublished

  • Systematic review and individual patient data meta-analysis of randomised trials
  • 1-stage approach

Authors' conclusion

Results of this systematic review and individual patient data meta-analysis suggest that compared with a high-intensity statin strategy, the alternative LDL cholesterol-lowering strategy demonstrated comparable efficacy regarding 3-year death or cardiovascular events in patients with ASCVD, with an associated reduction in LDL cholesterol levels and risk for new-onset diabetes and intolerance.

Study context

Population
Patients with atherosclerotic CVD (atherosclerotic cardiovascular disease (ASCVD))
Participants
8,180 patients · 2 RCTs
Comparison
Alternative LDL-C–lowering strategy vs high-intensity statin strategy
  • Alternative strategyn = 4,094
  • High-intensity statin strategyn = 4,086reference
Outcome
Composite of:
  • All-cause death
  • MI
  • Stroke
  • Coronary revascularization
Follow-up
3 years

Pooled result

As reported in the abstract

Hazard ratio

0.98

95% CI 0.84–1.15

P = 0.82

Events by group

Alternative strategy vs High-intensity statin strategy
HR 0.98 (95% CI 0.84–1.15); P = 0.82

Further pooled results

LDL-C during treatment

P < 0.001

Safety

New-onset DM

P = 0.047

Initiation of antidiabetic medication for new-onset DM

P = 0.02

Intolerance-related discontinuation or dose reduction

P < 0.001

Original publication

Alternative LDL Cholesterol–Lowering Strategy vs High-Intensity Statins in Atherosclerotic Cardiovascular Disease. JAMA Cardiol. Published 1 February 2025. doi:10.1001/jamacardio.2024.3911

Summarised from the published abstract; every number is checked against it